The Portuguese universal access program to direct-acting antivirals (Sovaldi® and Harvoni®) for the treatment of Hepatitis C : a financial analysis of the first 2 years by Esteves, Bernardo Augusto Pessoa de Amorim da Costa
 
 
 
 
 
 
 
 
The Portuguese universal access program 
to direct-acting antivirals (Sovaldi® and 
Harvoni®) for the treatment of Hepatitis C:  
 
A financial analysis of the first 2 years 
 
 
Bernardo Augusto Pessoa de Amorim da Costa 
Esteves 
 
 
 
 
Dissertation written under the supervision of Professor Susana 
Frazão Pinheiro 
 
 
 
Dissertation submitted in partial fulfilment of requirements for the 
International MSc in Management with Major in Strategy and Consulting, 
at the Universidade Católica Portuguesa, June 2017. 
2 
 
Abstract 
 
Title: The Portuguese universal access program to direct-acting antivirals (Sovaldi® and 
Harvoni®) for the treatment of Hepatitis C: A financial analysis of the first 2 years 
Author: Bernardo Augusto Pessoa de Amorim da Costa Esteves 
 
Nowadays, 350.000 people die annually due to the direct or indirect action of the Hepatitis 
C virus, responsible for many acute and chronic hepatitis worldwide and their further 
progression to more severe diseases like Hepatic Cirrhosis and Hepatocellular Carcinoma. 
Portugal is no exception as 150.000 people are estimated to be infected with related deaths up 
to 1.200 annually. 
Two years ago, after Gilead's development of two new drugs - Sovaldi® (Sofosbuvir) and 
Harvoni® (Sofosbuvir + Ledipasvir) - with treatment success rates around 95%, the Portuguese 
government took the decision of granting universal access to this drugs to all patients infected 
with the HCV, regardless of the stage of progression of the disease.  
The objective of this thesis is therefore to perform an economic analysis of this measure, 
understanding the impact, costs and benefits for the patients and healthcare system, what 
conclusions are willing to be taken and how can it influence future deals. 
The collection of data from the Infarmed press releases as well as previous studies enabled 
the comparison of the economic profit for the government when treating patients with Sovaldi® 
/ Harvoni® versus Pegylated Interferon and Ribavirin. The results showed that the new therapy 
is cost-effective, increasing HCV infected patients’ life expectancy while avoiding many severe 
occurrences.  
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Resumo 
 
Título: The Portuguese universal access program to direct-acting antivirals (Sovaldi® and 
Harvoni®) for the treatment of Hepatitis C: A financial analysis of the first 2 years 
Autor: Bernardo Augusto Pessoa de Amorim da Costa Esteves 
 
Actualmente, 350.000 pessoas morrem anualmente devido à acção directa ou indirecta do 
vírus da Hepatite C. Portugal não é excepção, uma vez que se estima que 150.000 pessoas 
estejam infectadas e que ocorram anualmente 1.200 mortes relacionadas com este vírus.  
Há dois anos atrás, após o desenvolvimento por parte da Gilead de dois novos fármacos – 
Sovaldi® (Sofosbuvir) e Harvoni® (Sofosbuvir + Ledipasvir) – com taxas de sucesso de 
tratamento à volta dos 95%, o governo português tomou a decisão de garantir o acesso universal 
destes fármacos a todos os pacientes infectados com o VHC, independentemente do estádio de 
progressão da doença. 
Esta tese pretende realizar uma análise económica desta medida, tentando calcular o 
impacto, os custos e os benefícios que pode trazer para os pacientes e para o Sistema Nacional 
de Saúde, tendo a noção que as conclusões obtidas poderão influenciar decisões futuras. 
Os dados recolhidos do Infarmed conjugados com o de estudos anteriores permitiram 
comparar os ganhos económicos para o Estado ao tratar pacientes com Sovaldi® / Harvoni® 
quando comparado com Interferão Peguilado e Ribavirina. No final, os resultados mostraram 
que a nova terapia é custo-efectiva, aumentando a esperança média de vida dos pacientes 
infectados com VHC e permitindo evitar um grande número de ocorrências graves. 
 
 
Palavras-chave: Hepatite C, Sovaldi, Harvoni, Sofosbuvir, Ledipasvir, Modelo de Markov  
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1. Introduction 
Nowadays, 350.000 people die annually due to the direct or indirect action of the Hepatitis 
C virus, responsible for many acute and chronic hepatitis worldwide and their further 
progression to more severe diseases like Hepatic Cirrhosis and Hepatocellular Carcinoma. This 
virus is spread out worldwide infecting 2,2% of the world population. Portugal is no exception 
as 150.000 people are estimated to be infected with related deaths up to 1.200 annually. 
Two years ago, after Gilead's development of two new drugs - Sovaldi® (Sofosbuvir) and 
Harvoni® (Sofosbuvir + Ledipasvir) - with treatment success rates around 95%, the Portuguese 
government took the decision of granting universal access to these drugs to all patients infected 
with the HCV, regardless of the stage of progression of the disease. The main purpose of this 
thesis is therefore to perform an economic analysis of this historical decision, considering the 
patients treated during the first two years. 
To evaluate this decision, a few analysis were done around its impact for the core 
stakeholders, the patients, as well as the economic benefits for the Government. Also important 
is whether this measure can be the basis for future similar decisions. The main research 
questions to focus on, are:   
 RQ1: What are the impact, cost and benefits of this measure for: 
 Patients 
 Healthcare system 
RQ2: What conclusions are achieved and how they can influence: 
 The near future 
 Similar measure (co-participation) for different diseases 
This thesis aims to have both academic and managerial relevance. As the government 
decision is relatively recent, this study will provide both the opportunity and the challenge to 
economically evaluate the first program of its kind. Also, if results are positive, it might serve 
as future ground for many other similar decisions in the healthcare sector. 
The dissertation is structured in five chapters: Introduction, Literature Review, 
Methodology and Data Collection, Results' Analysis and Main Conclusions and Further 
Research. 
10 
 
It will start with an overview of the dissertation’s topic and context, followed by a second 
chapter aiming to present some facts and figures about HCV, both in Portugal and worldwide. 
It explains the natural history of the disease and its associated costs, as well as the evolution of 
the treatments and an attempt to contextualize the Portuguese government decision. The last 
subchapter is related with the methods used by economists to choose between different 
measures.  
The third chapter explains the processes of data collection used to obtain the results and to 
answer the research questions. It also clarifies the methodology used to perform this economic 
analysis, splitting it between benefits and costs. The following chapter briefs the results 
gathered during the analysis of the results, once more separated between costs and benefits and 
applying the methods described previously. Its core function is to support the last chapter where 
the conclusions will be listed.  
In this last chapter, a summary of the answers to the research questions will be provided, 
stating the main results obtained and how can they influence future deals. Finally, the potential 
limitations that could affect results will be stated as well as possible research to be developed 
in the future. 
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2. Literature Review 
2.1 Facts and Figures 
Since its discovery in 1989, the Hepatitis C Virus (HCV) has been quickly spreading out 
around the world. Data from 2010 suggests that around 185 million individuals (2,2% of the 
world’s population) are infected with this disease and that 350 000 patients die every year 
(World Health Organization, 2014). Asia is considered the continent with the highest number 
of infected individuals, followed by Africa and Europe (Lavanchy, 2011).  
 
Figure 1 - Hepatitis C global prevalence 2010 (%) 
(Lavanchy, 2011) 
Since HCV is primarily transmitted through exposure to contaminated blood (Alter, 1995), 
population groups that have an increased risk of exposure to this disease include recipients of 
blood transfusions and derivatives before 1992, injection drug users, healthcare workers and 
HIV infected patients (Chak, Talal, Sherman, Schiff, & Saab, 2011). Nevertheless, it is fair not 
to forget high-risk sexual exposure as another means of transmission of the disease, as well as 
piercings and tattoos, accounting for 10-20% of HCV infections (Alter, 1997). 
According to a panel of experts, in 2013, 1-1,5% of the Portuguese population, or 100.000 
to 150.000 patients, is infected with HCV. However, only 30% (~37.500) are assumed to be 
diagnosed (Anjo et al., 2014; Baptista Leite, 2014). The annual HCV incidence rate in Portugal 
is one new case per 100.000 inhabitants, meaning 100 new cases per year (Anjo et al., 2014), 
while 900-1200 HCV related deaths are estimated annually (Baptista Leite, 2014).  
Furthermore, high percentages of HCV were found in endovenous drug users (50%), 
especially in long duration users (80%) and HIV co-infected patients (30%). Patients in 
hemodialysis (5%), blood transfusions receptors before 1992 (2%) and babies from HCV 
infected mothers (1,5%) were other identifiable risk groups (Anjo et al., 2014). 
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2.2 Natural History of HCV 
The Natural History of Hepatitis C is highly variable, ranging from acute and chronic 
hepatitis, to cirrhosis, hepatocellular carcinoma (HCC) and death (EASL, 2015). When entering 
the human body, HCV lasts around 15-150 days to incubate (Aranda da Silva, 2006). During 
its acute stage, the majority of the patients are still asymptomatic and while some spontaneously 
eradicate the virus, the majority (54-86%) establish a chronic infection (Maasoumy & 
Wedemeyer, 2012). In this stage, 15-51% of the patients develop cirrhosis at a given moment 
in life, influenced by several factors like alcohol consumption, diabetes, aging or HIV co-
infection (Maasoumy & Wedemeyer, 2012). The Metavir scoring system is currently accepted 
for the liver fibrosis staging.  
 
Figure 2 - METAVIR liver biopsy scoring system 
 (WHO, 2014)  
At F4 stage, patients have already developed cirrhosis and can progress from a compensated 
phase of the disease to a decompensated one associated with portal hypertension and hepatic 
insufficiency, causing jaundice, ascites, digestive bleeding and infections (Anjo et al., 2014). 
Annually, 3-6% of the cirrhotic patients have a severe liver decompensation, which increases 
the mortality ratio to 18% in the next year and 50% in a 5 year period (Maasoumy & 
Wedemeyer, 2012).  
The Hepatitis C Virus has also an oncogenic potential and estimations state that the virus 
causes approximately 25% of the Hepatocellular Carcinomas (HCC) worldwide (Tanaka et al., 
2006). Plus, the incidence of HCC cases is higher in cirrhotic patients (1,4 - 4,9% per year), 
being the overall five-year HCC risk between 7-30%. (Lok et al., 2009).  
Concerning Portugal, estimations showed that 60% of the diagnosed patients were in the 
chronic hepatitis C state (CHC), while the rest of the patients were split between compensated 
cirrhosis (30%), decompensated cirrhosis (6%) and HCC (4%) (Anjo et al., 2014). Although in 
the last years a reduction on the number of new infected patients has been noticed, until 2030 
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there will be an increase on the number of patients in the higher stages of the disease (45%, 
100% and 80%), respectively (Baptista Leite, 2014). 
Also, HCV is considered the main cause for transplants associated to viral infections while 
in Portugal a panel of experts estimated that 20% of the hepatic transplants were due to HCV, 
meaning 50 out of an annual average of 250 liver transplants, expecting to increase in the near 
future (Baptista Leite, 2014). 
 
Figure 3 - Natural History of HCV infection 
 (Maasomy and Wedemeyer, 2012) 
2.3 Associated costs 
To analyze the economic impact of the HCV infection, both direct and indirect costs should 
be calculated. As far as direct costs are concerned, both the costs of medication exclusive for 
hospitals and in ambulatory are included. Furthermore, specialized appointments, diagnostic 
and therapeutic complementary exams and medication for transplanted patients are also 
considered. As indirect costs, absenteeism or the loss of productivity are included in the list 
(Anjo et al., 2014).  
In Portugal, the most recent studies estimate that the annually HCV associated costs are 
around 70 million euros (Anjo et al., 2014; Baptista Leite, 2014). These are mainly related to 
the more advanced stages of the disease and do not include anti-viral costs. Taking into account 
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the estimations to 2030, annual direct costs will ascend as high as 2.100 million euros.(Baptista 
Leite, 2014).  
In a study from 2013, the annual average cost per patient and per stage in Portugal was 
estimated in 432€ for CHC, 522€ for compensated hepatic cirrhosis, 11.103€ for 
decompensated hepatic cirrhosis and 17.128€ for HCC. Regarding transplanted patients, the 
average annual costs were estimated as 116.154€ in the first year and 6.886€ for the following 
years. The annual costs per stage of the disease are summarized on the plot below (Figure 4). 
Indirect costs were not considered, as there is no absenteeism in chronic hepatitis and 
compensated cirrhotic patients, only less than 20% of the decompensated hepatic cirrhosis were 
workers (from the 10% in that stage) and with an advanced average patient age (Anjo et al., 
2014)  
 
Figure 4- Annual Costs per Stage of the disease in Portugal 
(Adapted from Anjo et al. 2014) 
2.4 HCV Treatment  
Currently, 6 different HCV genotypes (G) have been identified (Naggie, 2012), as well as 
50 subtypes (Aranda da Silva, 2006). Determining each patient genotype is crucial as it 
influences the type of treatment and its duration (José Velosa, Caldeira, Lopes, Guerreiro, & 
Marinho, 2012). Genotype 1 is predominant in the USA and in Europe, G4 and G5 in Africa 
and G6 in Asia. Portugal is no exception in the European continent, as studies show that the 
dominant genotype is G1 (60%), followed by G3 (30%), G4 (10-15%) and G2 (2%) (Baptista 
Leite, 2014; J. Velosa et al., 2011). 
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The goal of the HCV therapy is to eradicate the virus. Nowadays, it is considered that the 
infection is cured in patients who achieve a Sustained Virological Response (SVR): 
undetectable HCV RNA, 12 - 24 weeks after treatment completion. Nevertheless, cirrhotic 
patients remain at risk of having severe complications, even after curing the infection (EASL, 
2015).   
Before 2011, the standard treatment for chronic hepatitis C was a combination of Pegylated 
Interferon alfa (PegIFN) and Ribavirin (RBV) for 24 or 48 weeks (José Velosa et al., 2012). 
However, while for patients infected with G2, G3, G5 or G6, SVR rate was 80% or higher, for 
patients with genotype 1 rates were around 40-50% (Antaki et al., 2010). Plus, this treatment 
was contra-indicated in several groups of patients (EASL, 2011; José Velosa et al., 2012).  
In 2011, in order to suppress the gap in the HCV G1 treatment effectiveness, Boceprevir 
(BOC) and Telaprevir (TVR) were licensed to the market. These two drugs were the first of a 
new generation of direct-acting antivirals (DAA), and together with PegIFN and RBV, were 
able to increase SVR to rates to 65-75% (Bacon et al., 2011). Still, the side effects and the high 
costs of this triple combination influenced its weak market acceptance and success (EASL, 
2015). 
Currently, Sofosbuvir (SOF), a drug produced by Gilead and licensed in 2014, is 
recommended by the most recent international guidelines for the treatment of CHC patients 
(EASL, 2015), as it showed unparalleled SVR rates and tolerability (European Medicines 
Agency, 2013). Plus, combined with ribavirin and/or Simeprevir and Daclatasvir, two other 
DAA licensed in 2014, it showed rates of 60-100% depending on the HCV genotype (EASL, 
2015). The combination of Sofosbuvir with another Gilead owned medicine, Ledipasvir (LDV), 
resulted in SVR rates around 94% for G1 HCV patients (Afdhal, Reddy, et al., 2014; Afdhal, 
Zeuzem, et al., 2014; Guzman Sabrina, 2014; Kowdley et al., 2014). These new drugs had the 
advantage of being taken as a pill once per day when compared with the former treatments: 5-
6 pills per day (RBV) or subcutaneous (PegIFN) (Aranda da Silva, 2006; EASL, 2015). 
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Figure 5 - Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic 
hepatitis C without cirrhosis  
(EASL 2015) 
 
Figure 6 - Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic 
hepatitis C with compensated cirrhosis 
(EASL 2015) 
 
2.5 The Portuguese Government Decision 
Before 2014, the standard HCV treatment was similar to the rest of the world: Pegylated 
Interferon alfa combined with Ribavirin at first, followed by a triple treatment with both 
combined with Boceprevir or Telaprevir when they became available (Anjo et al., 2014; José 
Velosa et al., 2012). From the moment Gilead obtained its license to sell Sofosbuvir and 
Ledipasvir, the interest demonstrated by Portuguese patients in these new drugs was significant. 
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However, the fact that it was only accessible by wealthy patients (40.000 euros /patient) 
(Favreau, 2014) and the incapacity of the Portuguese government to reach an agreement with 
Gilead lead many patients to demonstrate their dissatisfaction in the media and even in the 
Portuguese parliament (Lusa, 2015). The government had at the time an emergency plan, 
consisting in treating with this medicine only patients with decompensated cirrhosis awaiting 
for a liver transplant (Castanho, 2014). 
In February 2015, after one year of negotiations, the Portuguese Ministry of Health initiated 
a new HCV treatment policy, granting universal access to this new generation of direct-acting 
antivirals, specifically Sovaldi® (Sofosbuvir) and Harvoni® (Sofosbuvir + Ledipasvir), to all 
patients registered in the National Healthcare System. (Infarmed, 2015). It was considered an 
unprecedented measure, aiming to increase the life expectancy of HCV infected patients, while 
decreasing public expenditures (Infarmed, 2015). 
 
Figure 7- Modelled regimens and respective SVR estimates for HCV genotype 1 subgroups 
(Almeida JM, Felix J et al. 2015) 
According to the former Portuguese Health Minister, Paulo Macedo, the Government had 
granted “Europe’s best deal”, explaining that Gilead would only be paid per patient as long as 
the treatment proved to be successful. Plus, regardless of the duration of the treatment, 8, 12 or 
24 weeks, the government would always pay the same, less than 20.000 € per patient (RTP, 
2015). The agreement would have the duration of two years, expecting to treat 7000 to 8000 
patients in this time span (Carriço, 2015), while a national registry would be created for 
collecting information about the success of the treatment, the so-called Portal of Hepatitis C 
(Tato Marinho, 2016). 
At the end of July 2015, Infarmed (the Portuguese national authority for drugs and health 
products) had estimated that around 5000 patients had been treated, while 2184 premature 
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deaths were spared. Furthermore, 217 hepatic transplants, 1200 HCC and 3204 cirrhosis 
incidents were avoided, resulting in treatment cost savings of 166 million euros (Infarmed, 
2015). 
2.6 Economic Evaluation in Healthcare 
Different forms of economic evaluation are used to assist economists in decision making 
between different courses of action. Although the most appropriate method of economic 
evaluation depends always on the context, the most straight-forward approach should always 
be applied (Robinson, 1993d). 
2.6.1 Cost-Benefit Analysis 
Being the most comprehensive of all the economical evaluations, the cost-benefit analysis 
consists on listing the potential advantages and disadvantages of an option, so that the best 
choice can be made (Robinson, 1993d). Monetary values are put on both inputs (costs) and 
outputs (benefits), making it possible to say if a program offers a net gain to society whenever 
total benefits are higher than total costs. Although early valuation of benefits’ methods were 
based on the human capital approach, being outcomes valued in terms of productivity gains, 
recent methods adopted valuations based on peoples’ preferences, their willingness to pay.  
Nevertheless, when using this method economists need to be capable to understand that the 
value people give to money is often included in the valuation of the benefits of the healthcare 
program (Robinson, 1993a). Since the 1930s, it has been applied to healthcare programs and 
become a framework for all other forms of economic evaluations, such as the cost-effectiveness 
or the cost-utility analysis (Robinson, 1993d).  
2.6.2 Cost-Effectiveness Analysis 
The cost-effectiveness analysis is used to compare the costs of different programs when 
outcomes are in common natural units. When measuring healthcare procedures, data is ideally 
collected from economical evaluations in clinical trials, being the outcomes returned in life 
years gained, cases cured or even occurrences avoided. Procedures are then expressed in costs 
per unit of outcome. Although there is some disagreement among economists about whether 
benefits should be discounted, the traditional view still requires it, so that long-term effects do 
not become so cost effective. Furthermore, whenever there is uncertainty about the outcomes, 
a sensitive analysis should be performed. (Robinson, 1993b). Despite being the most applied 
approach until 10 years ago, this type of analysis have certain limitations, not being able to help 
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economists decide between treatments for different diseases or to analyze reductions in 
morbidity and mortality in a single index (Robinson, 1993d). 
2.6.3 Cost-Utility Analysis 
To overcome cost-effectiveness analysis limitations, economists developed the cost-utility 
evaluation, a more sophisticated approach. It enable economists to choose between different 
strategies in the healthcare sector using utility, the level of well-being experienced by people in 
different states of health. Life scales such as the Quality-Adjusted Life Years (QALYs) 
(Appendix 1), have been created so that a single measure of lifetime utility can be obtained 
from a utility-based quality of life in a given health state and a quantitative measure of life years 
(Robinson, 1993d).  
In order to compare different program’s outcomes, indexes such as the Rosser’s combined 
categories of two dimensions, disability and distress, obtaining different health states. Scores 
were then expressed in terms of 0 = Dead to 1 = Perfect Health, becoming possible to assign a 
Quality of Life (QoL) score, to any health state (Robinson, 1993c). This index has later become 
the role model for more complex questionnaires, such as the EuroQoL 5 Dimensions 
Questionnaire (EQ-5D) (Appendix 2).   
By obtaining a common unit of utility, different interventions can be compared and ranked 
using an index measured in cost per QALYs gained, called Incremental Cost-Effectiveness 
Ratio (ICER) (Appendix 3). Nevertheless, there are some controversy about this type of 
analysis as it is not consensual how to value a health status or an improvement in health status. 
(World Health Organization, 2003). 
2.6.4 Markov Models in Economical Evaluations 
Markov models (Appendix 4) are used to evaluate random processes that evolve over time. 
In healthcare, they are often employed for decision making, particularly when modelling the 
progression of chronic diseases (Briggs & Sculpher, 1998).  
In order to be a realistic and effective model, the disease must be divided into different 
states, representing mutually exclusive events (clinically and economically). Transition 
probabilities should also be assigned between the states, being constant over time. The 
probability of moving to states in each cycle must sum 1, as the probability of staying in the 
same state is also calculated (1-Probability of Leaving). . Therefore, by running the model over 
a selected number of cycles (discrete time period), it is possible to estimate long term costs and 
outcomes associated with the intervention (Briggs & Sculpher, 1998).  
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 QALYs and costs for the given interventions can then be calculated using these models. 
For QALYs the procedure is to attach a QoL weight to for a given state of health, generating a 
result in the end of several cycles. Costs however are easier to be calculated if they are attached 
to transition probabilities as well, representing treatments.  
Nevertheless, when computing the model both costs and outcomes should be discounted. 
By applying a rate of discount, they can therefore be compared in terms of a Net Present Value. 
As an outcome of the model, it is possible to calculate the incremental costs or the incremental 
effectiveness of a drug therapy by computing the ICER, using the costs and the effects 
(normally the QALYs) estimated in the Markov model  (Briggs & Sculpher, 1998). 
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3. Methodology and Data Collection 
3.1 Study Design 
This economic analysis aimed to analyze the impact of the Portuguese government decision 
of granting universal access to the new direct-acting antivirals to all patients infected with HCV.  
For that matter, primary data was requested to Infarmed regarding information about 
Portuguese patients collected by the agency on their HCV portal. Given the reluctance of the 
institution on providing data, the same was retrieved from a poster for EASL 2016 congress 
from Professor Rui Tato Marinho, using data from the database and revealing patients’ 
distribution per HCV genotype and degree of liver fibrosis (Tato Marinho, 2016). This 
information was of great importance so that costs and benefits could be calculated with more 
accuracy. 
In February 17th 2017 the total of initiated treatments was 10.168 (Infarmed, 2017b), being 
the distribution of treated patients per genotype and degree of liver fibrosis as follows: 
 
Table 1- Treated Patients per HCV Genotype (designed from data) 
 
 
Table 2 - Treated Patients per degree of Liver Fibrosis (designed from data) 
3.2 Costs 
There were two main types of direct costs considered on this analysis. The cost of the new 
medication consists on the total Hepatitis C treatment costs of the new therapy for this cohort 
of patients. The cost of non-treated patients included all the costs associated with patients that 
did not respond to treatment throughout the progression of the disease along its natural history. 
6921 68,07%
129 1,27%
1821 17,91%
1275 12,54%
21 0,21%
G4
G5/G6
G1
G2
G3
Treated Patients per HCV Genotype
G1 G2 G3 G4 G6 Total
208 8 36 38 0 290
1453 31 291 293 4 2073
1592 28 364 281 6 2271
1523 19 382 281 4 2209
2146 43 747 383 8 3326
Treated Patients per degree of Liver Fibrosis
F4
F0
F1
F2
F3
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3.2.1 Medication Costs 
The cost of the new medication (Harvoni® and Sovaldi®) was not disclosed by the Health 
Ministry. Nevertheless, values close to 20.000€ - 24.000€ per treatment became public (Carriço, 
2015; RTP, 2015), even without quantity discounts, so a sensitivity analysis with cost levels 
close to this amount will be used to assess the predictable gains for the government (24.000€, 
20.000€ and 15.000€). 
On the other side, the old medication (Pegylated Interferon and Ribavirin) cost was 
estimated for the Portuguese case, taking into account estimations from 2013 actualized for 
2017. Experts assumed that 70% of patients infected with genotypes 1-4 took Pegylated 
Interferon 2a + Ribavirin, while 30% Pegylated Interferon 2b + Ribavirin. The average duration 
of treatments was also estimated, ranging from 30 weeks for G2 and G3 patients and 36 weeks 
for G1 and G4 patients (Anjo et al., 2014). In the end of treatments, a total of 6.077.531€ for 
all patients in medical appointments and complementary diagnostic exams would have to be 
added to total medicine costs (Table 3). Portuguese HCV genotypes 5 and 6 patients are 
residual, so inherent costs were not calculated. 
 
Table 3 - Old Medication therapy schematics (designed from data)  
3.2.2 Non-treated patients’ costs 
Concerning the cost of non-treated patients, two groups were considered. The first one 
included all patients with F0-F3 liver fibrosis and the second gather all the patients with F4, 
that is, hepatic cirrhosis. The rationale behind this decision was that HCV patients treated before 
cirrhosis had minimal chances of evolving to higher stages of the disease. F0-F2 patients are 
considered cured. F3 patients are only kept into periodical analysis for Hepatocellular 
Carcinoma screening. Also, cirrhotic and non-cirrhotic patients respond differently to the two 
treatments as SVR is lower in cirrhotic patients (Floreani, 2008; Rodrigues, 2016).  
Although this new therapy has increased substantially the overall success rate to levels close 
to 100% (96,5% SVR) (Infarmed, 2017a), there are still patients whom the new medicine was 
not successful. They continue progressing through the natural history of the disease to more 
advanced stages. 
Genotype Patients Medication Weekly cost Average duration (weeks)
70% PegIFN 2a + RBV 225,48 €
30% PegIFN 2b + RBV 170,06 €
70% PegIFN 2a + RBV 223,76 €
30% PegIFN 2b + RBV 168,35 €
361, 4
2, 3 30
PegIFN + RBV
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In order to understand how progression was made, a Markov model of the disease was 
followed (Figure 8), considering a period of 60 years. The reason behind this lifetime span was 
to give enough time for all the patients in the model to reach the death stage so that costs could 
be calculated with more certainty. In order to do so, the average age of the cohort (51,2 years) 
and INE mortality tables were taken into consideration, so that the probability of mortality from 
other causes could be added to the model. 
 
Figure 8 - Simplified HCV Markov model (designed from data) 
 
The number of patients in every stage, from F0 to F4, was multiplied by the non-SVR rate 
of this treatment for both cirrhotic and non-cirrhotic patients and then by the annual percentage 
of evolution to further stages of the disease (Table 4) for every year of the model.  
 
Table 4 - Percentage of Evolution/year between HCV stages (designed from data) 
 
After 60 years, the amount of occurrences in every stage of the disease unable to be avoided 
were then multiplied by the cost per stage per year per patient of the disease (Anjo et al., 2014). 
These costs had into consideration medical appointments, blood tests, complementary exams, 
abdominal ultrasounds and even hospitalizations and were actualized at a 5% rate according to 
Stages % Evolution/year Source
F0-F1 11,7% Thiem et al. 2008
F1-F2 8,5% Thiem et al. 2008
F2-F3 12,0% Thiem et al. 2008
F3-F4 11,6% Thiem et al. 2008
Cirrhosis - Hepatic Decompensation 3,9% Fattovich et al. 1997
Cirrhosis - HCC 1,4% Fattovich et al. 1997
Hep. Decompensation - HCC 1,4% Fattovich et al. 1997
Hep. Decompensation - Liver transplant 2,0% Grieve et al. 2006
Hep. Decompensation -Death 13,0% Fattovich et al. 1997
HCC - Death 43,0% Fattovich et al. 1997
Liver transplant - Death (1y) 15,0% Grieve et al. 2006
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Infarmed specifications (Table 5) becoming higher as the disease continues to progress. Liver 
transplantations had also into consideration costs for the first 10 years after the procedure, as 
well as the annual probability of death on the first year. Although there is no consensual 
decision among economists about how and whether or not to value a death, the decision of not 
accounting those costs was taken. 
Since this cohort of patients is relatively similar to the one used in the previous study, 
including also the Portuguese HCV infected patients (Anjo et al., 2014) and that concluded that 
indirect costs were not relevant, they were not considered in this analysis.      
Lastly, in order to compare the total non-responding patients’ costs with the new treatment 
with the old treatment the same procedure was computed. Different SVR rates for both cirrhotic 
and non-cirrhotic patients were taken into consideration, when being treated with the two 
medications, 91,6% / 98,2% for the new therapy and 45,9% / 65,8% for the old therapy 
(Floreani, 2008; Rodrigues, 2016).  
It is fair not to forget that many patients now treated with DAA agents are in reality non-
responders to PEG-IFN, ~40% (Martins et al., 2016). Some could not bear its side-effects and 
a few have medical conditions that contra-indicated the old treatment.  
 
Table 5- Cost per HCV stage per year per patient for 2017 
(Adapted from Anjo et al. 2014) 
3.3 Benefits 
3.3.1 Lifetime Savings and Reduction of Occurrences 
As far as benefits are concerned, a reduction on the number of patients with cirrhosis, 
hepatocellular carcinomas, liver transplants and premature HCV-related deaths are among 
them. Lastly, the most important economic benefit to be taken into account by the Portuguese 
government are the lifetime savings. 
With a non-cirrhotic SVR of 98.2%, almost all group 1 patients (F0-F3) become cured 
(Rodrigues, 2016), not evolving to further stages of the disease and contributing to a decrease 
Stages of the disease Cost / stage /year / patient
CHC (F0 - F3) 432 €
Cirrhosis (F4) 522 €
Hepatic Decompensation 11.103 €
HCC 17.128 €
Liver Transplant 185.014 €
Death 0 €
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on the number of cirrhosis, HCC and even deaths taking into account the annual transition 
probabilities. Nonetheless, the 1.8% non-treated non-cirrhotic patients will be accounted as 
costs and progress to further stages of the disease.  
On the other side, SVR for cirrhotic patients (Group 2) is 91.6% (Rodrigues, 2016) what 
can enlarge the number of HCC, Decompensated Cirrhosis and deaths avoided, considering 
HCV transition probabilities. Once again, non-responding patients (8.4%) will be considered 
as costs and progress to further stages of the disease. 
After obtaining these numbers for a 60 years lifetime span, it will be possible to calculate 
the lifetime savings by multiplying the costs per stage per year per patient discounted at a 5% 
rate by the number of occurrences avoided annually in each stage of the disease, throughout the 
lifetime of the model. Nevertheless, to compare with the previous treatment, the same method 
will have to be computed taking into account SVR for both cirrhotic and non-cirrhotic patients. 
3.3.2 QALYs and ICER 
The Quality-Adjusted Life-Years estimate the years of life remaining for a patient following 
a particular treatment or intervention. QALYs for a given treatment are calculated by 
multiplying the average number of years spent by a patient in a given stage of the disease by a 
quality-of-life score on a 0 to 1 scale. The Quality of Life utilities (QoL) were attributed by 
patients and measured in terms of the person’s ability to perform daily life routine and freedom 
from pain and mental disturbance in the different states of health (NICE, n.d.). By obtaining the 
different QALYs per treatment, it was possible to understand whether the new treatment is more 
effective than the old one and how is it reflected in the average life expectancy of HCV infected 
patients.  
In this analysis, utility values were retrieved from a previous study, and showed a quality of 
life of 0,81 for HCV infected non-cirrhotic patients, 0,55 for HCV infected cirrhotic patients 
and the same utility, 0,45, for patients with Decompensated Cirrhosis, Hepatocellular 
Carcinoma and Liver Transplant (Table 6). 
 
Table 6 - Old Medication costs per genotype (Designed from data) 
Stages Utility /QoL Source
Non-cirrhotic 0,81 Siebert U et al. 2002
Compensated Cirrhosis 0,55 Siebert U et al. 2002
Decompensated Cirrhosis 0,45 Siebert U et al. 2002
Hepatocellular Carcinoma 0,45 Siebert U et al. 2002
Liver Transplant 0,45 Siebert U et al. 2002
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In order to understand whether the new treatment is cost-effective when comparing with the 
old one, the Incremental Cost-Effectiveness Ratio (ICER) indicator should be taken into 
consideration. It is the ratio of the change in costs of the two different therapies with the change 
in the effects of the intervention measured in quality-adjusted life-years. 
Several countries define different cost-effectiveness thresholds (WTP), above which 
treatments are no longer cost-effective. In the United Kingdom the National Institute for Health 
and Care Excellence (NICE) sets a threshold of £30.000 per QALY (Appleby, 2007), so this 
rule will be used in order to assess whether this new therapy is cost-effectiveness. 
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4. Results’ Analysis 
4.1 Medication Costs 
Old medication therapy costs were calculated taking into account the distribution of the 
cohort by genotype. HCV G1 and G4 therapy lasted 36 weeks on average, while HCV G2 and 
G3 lasted 30. In the end, adding up monitoring costs, total costs amount 79.822.699€ (Table 
7). 
 
Table 7 - Old Medication costs per genotype (designed from data) 
Since new therapy costs are still not disclosed, a sensitivity analysis was conducted so that 
it could be possible to calculate whether the decision of treating patients with Sofosbuvir or 
Sofosbuvir + Ledipasvir was economically profitable to the government.  
As it is observable on the table below (Table 8), patients infected with HCV genotypes 1, 
4, 5 and 6, representing the majority of the cohort, were treated only with Sofosbuvir or 
Sofosbuvir + Ledipasvir, while for patients infected with G2 and G3, Ribavirin (65€ per week) 
had also to be taken into account. For these two HCV genotypes, the treatment duration is 12 
and 24 weeks.  
Total medication costs were then tested for three different cost levels of Sofosbuvir / 
Sofosbuvir + Ledipasvir. In the first scenario, 24.000€, total costs for the new medicine would 
amount 244.034.336€. In the second scenario, a cost level of 20.000€ per patient would return 
total costs of 203.362.336€. Lastly, a lower cost of 15.000€ per patient would result in 
152.522.336€ in costs. 
 
Table 8 - Cost of treating HCV patients with the new medicine for different costs per treatment levels 
(designed from data) 
 
Genotype Patients Medication Weekly cost Average duration (weeks) Costs Monitoring costs Total
70% PegIFN 2a + RBV 225,48 € 46.572.130,93 €
30% PegIFN 2b + RBV 170,06 € 15.054.078,18 €
70% PegIFN 2a + RBV 223,76 € 9.164.121,30 €
30% PegIFN 2b + RBV 168,35 € 2.954.837,62 €
PegIFN + RBV
1, 4
2, 3 30
36
6.077.531,25 € 79.822.699,28 €
Genotype Patients Treatment Average duration (weeks) Cost SOF / LDV Cost RBV / Week (a) Cost per Genotype Total
1, 4-6 8218 SOF / LED 12 197.226.662 €
2 129 SOF / LDV + RBV 12 3.099.985 €
3 1821 SOF / LDV + RBV 24 43.707.688 €
1, 4-6 8218 SOF / LED 12 164.355.552 €
2 129 SOF / LDV + RBV 12 2.583.451 €
3 1821 SOF / LDV + RBV 24 36.423.333 €
1, 4-6 8218 SOF / LED 12 123.266.664 €
2 129 SOF / LDV + RBV 12 1.937.783 €
3 1821 SOF / LDV + RBV 24 27.317.889 €
(a) Source: Prontuário Infarmed
New Medication
244.034.336 €
65 € 203.362.336 €
152.522.336 €
24.000 €
20.000 €
15.000 €
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4.2 Non-treated patients’ costs 
Costs representing the non-responding patients to the new treatment were computed, taking 
into consideration the new SVR rates for a 60 years period. In the beginning (Y=0), 403 patients 
did not respond to the treatment, split between 123 untreated CHC and 279 cirrhosis. From this 
point on, for a period of 60 years and according to the annual transition probabilities supra 
mentioned (Table 4), 11 Hepatic Decompensations and 4 Hepatocellular Carcinomas will occur 
in Year 1. Sixty years from now, all patients will be on the death stage, resulting in a present 
value of total non SVR patient costs of 22.602.901€ (Table 9).  
As a means of comparison between treatments, costs representing non-responding patients 
to the old treatment were also computed. Taking into consideration the former SVR rates for 
both cirrhotic and non-cirrhotic patients for a lifespan of 60 years, it is clear to see that costs 
will be higher, as 4140 patients were incapable of becoming cured with the old therapy, being 
99 HCV infected patients in F0 liver fibrosis stage, as well as 709 F1, 777 F2 and 755 F3 and 
1799 cirrhotic patients. This will result in more occurrences of further stages of disease. The 
present value of total non-responding patients to the old medicine costs will amount 
191.994.899€ sixty years from now (Table 9).  
 
Table 9 - Progression of non-responding patients in New vs Old Medication and its cost for a 60 year period 
(designed from data) 
 
As it is clear to understand, a higher SVR new medication rate influences the amount of 
non-responding patients’ costs to decrease significantly, less 169.392.808€ when comparing to 
the former therapy. The maximum difference between costs happens in year 10, when non-SVR 
Stages of the disease Cost / stage /year / patient 0 1 2 3 4 60
F0 5 5 4 4 3 0
F1 37 35 32 30 27 0
F2 41 39 37 35 33 0
F3 40 40 40 39 39 0
Cirrhosis (F4) 634 € 279 268 258 248 238 0
Hepatic Decompensation 13.496 € 11 19 26 31 0
HCC 20.819 € 4 6 7 8 0
Liver Transplant 224.886 € 0 1 1 0
Death 0 € 1 6 13 21 403
PV Costs 241.946 € 438.041 € 599.690 € 732.810 € 840.049 € 0 € 22.602.091 €
Stages of the disease Cost / stage /year / patient 0 1 2 3 4 60
F0 99 87 77 67 59 0
F1 709 658 610 565 522 0
F2 777 741 705 670 634 0
F3 755 758 756 750 740 0
Cirrhosis (F4) 634 € 1799 1785 1771 1758 1744 0
Hepatic Decompensation 13.496 € 70 128 175 214 0
HCC 20.819 € 25 40 49 55 0
Liver Transplant 224.886 € 1 4 7 0
Death 0 € 14 51 102 164 4140
PV Costs 2.370.579 € 3.598.188 € 4.645.876 € 5.542.847 € 6.298.025 € 0 € 191.994.899 €
New Medication (SVR Cir = 91,6% |SVR NCir = 98,2%)
525 €
Old Medication (SVR Cir = 45,9% |SVR NCir = 65,8%)
525 €
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costs for the old medication represent 8.187.907€, while the maximum new medication costs 
spent in a year was 1.053.315€ (Figure 9). 
 
Figure 9 - Progression of Total Costs for non-responding patients in New vs Old Medication for a 60 year 
period (designed from data) 
 
4.3 Lifetime Savings in Occurrences Avoided 
Regarding Lifetime Savings in Occurrences Avoided, by treating the cohort of patients with 
the old medication (Pegylated Interferon + Ribavirin), splitting patients according to its degree 
of fibrosis and applying the correspondent SVR rates for both cirrhotic and non-cirrhotic, 6029 
patients, 4503 Chronic Hepatitis C (191 F0, 1364 F1, 1494 F2, 1454 F3) and 1527 cirrhosis 
would have been treated successfully. That would have prevented 59 Hepatic Decompensations 
and 21 Hepatocellular Carcinomas from happening in the end of the first year. Sixty years from 
now, the Present Value of the lifetime savings for the government, concerning this cohort of 
patients and applying  annually discounted prices, would have summed 238.434.133€ (Table 
10).  
By treating patients with the new treatment, SVR rates increase significantly, which will 
result in 9766 successfully treated patients, distributed by 6720 chronic hepatitis C (285 F0, 
2036 F1, 2230 F2, 2169 F3) and 3047 cirrhosis. 118 Hepatic Decompensations and 43 
Hepatocellular Carcinomas were avoided in the end of the first year. In a 60 years period, 
Lifetime Savings for the new medication would amount 407.826.941€ (Table 10). 
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Table 10 - Progression of responding patients in New vs Old Medication and its cost for a 60 year period 
(designed from data) 
Once more, as it is clear to observe, as a result of a more effective SVR, the new medication 
increases substantially the savings in occurrences. It will always return higher savings during 
the lifetime span of the model, reaching its peak 11 years from now, when the government will 
be able to save 16.523.804€ (Figure 10). On the other side, treating patients with the old therapy 
will return a maximum of 9.424.527€ on savings in the end of year 12. 
 
Figure 10 - Progression of Lifetime Savings for responding patients in New vs Old Medication for a 60 year 
period (designed from data) 
4.4 Reduction in Occurrences 
By treating HCV infected patients with the new medication (Harvoni® and Sovaldi®), it will 
be possible to observe in the long-term that a larger number of occurrences will not happen.  
Stages of the disease Cost / stage /year / patient 0 1 2 3 4 60
F0 285 251 220 194 170 0
F1 2036 1889 1751 1621 1499 0
F2 2230 2128 2025 1923 1822 0
F3 2169 2178 2171 2154 2125 0
Cirrhosis (F4) 634 € 3047 3126 3200 3268 3330 0
Hepatic Decompensation 13.496 € 118 220 307 383 0
HCC 20.819 € 43 69 87 99 0
Liver Transplant 224.886 € 2 6 12 0
Death 0 € 34 107 206 326 9766
PV Costs 5.461.632 € 7.477.186 € 9.262.848 € 10.852.166 € 12.245.784 € 0 € 407.826.941 €     
 PV QALYs 7119 6679 6247 5831 5433 0 89.161                 
Stages of the disease Cost / stage /year / patient 0 1 2 3 4 60
F0 191 168 148 130 114 0
F1 1364 1266 1173 1086 1005 0
F2 1494 1426 1357 1288 1221 0
F3 1454 1459 1455 1443 1424 0
Cirrhosis (F4) 634 € 1527 1609 1686 1758 1824 0
Hepatic Decompensation 13.496 € 59 112 159 200 0
HCC 20.819 € 21 35 45 52 0
Liver Transplant 224.886 € 1 3 6 0
Death 0 € 21 62 117 183 6029
PV Costs 3.332.999 € 4.317.039 € 5.216.662 € 6.042.129 € 6.787.808 € 0 € 238.434.133 €     
PV QALYs 4487 4209 3938 3678 3429 0 56.592                 
New Medication (SVR Cir = 91,6% |SVR NCir = 98,2%)
525 €
525 €
Old Medication (SVR Cir = 45,9% |SVR NCir = 65,8%)
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The table below (Table 11) resumes the difference in the number of occurrences avoided, 
being the new treatment capable of preventing 3693 cirrhosis, 2458 Hepatic Decompensations, 
1083 Hepatocellular Carcinomas, 286 Liver Transplants and 3737 premature HCV-related 
deaths from happening during the 60 years lifetime span. 
 
Table 11- Number of occurrences in a 60 years period (New vs Old Medication) (designed from data) 
On the other hand, the higher number of occurrences avoided with the new therapy will be 
also reflected in higher savings per HCV stage at the end of the 60 years. In the table below, it 
is possible to observe that 169.392.808€ in total will be saved by treating patients with Sovaldi® 
and Harvoni® when compared to the former therapy, being the total difference between 
treatments of be 16.659€. By saving 11.556.121€ in the F0-F3 stage, as well as 14.456.779€ in 
the Cirrhosis stage, 51.599.019€ in Hepatic Decompensations, 15.631.903€ in Hepatocellular 
Carcinomas and 169.392.808€ in Liver Transplants, the government can therefore save money 
when treating Hepatitis C infected patients (Table 12). 
 
Table 12 - Savings in occurrences for a 60 years period in New vs Old Medication (designed from data) 
4.5 Sensitivity Analysis 
In order to analyze total costs for both therapies, three different scenarios were built taken 
into consideration the different cost levels for the new therapy (24.000€, 20.000€ and 15.000€). 
The old therapy cost (Pegylated Interferon + Ribavirin) remains unaltered, amounting 
79.822.699€. Also, as previously seen, non-responding patients’ costs are 191.994.899€ with 
the old therapy and 22.602.091€ with the new therapy.  
In the first scenario, when the new medication costed 24.000€ per treatment, the total cost 
per treatment amounted 244.034.336€, resulting in a total difference in savings in costs between 
therapies of 5.181.172€ and a difference in total cost per patient of -510€. The second scenario, 
Ocurrences Avoided New Medication Old Medication Diference btw treatments
Cirrhosis (F4) 9634 5940 3693
Hepatic Decompensation 6345 3887 2458
HCC 2792 1710 1083
Liver Transplant 735 449 286
Premature HCV-related deaths 9766 6029 3737
Lifetime Savings New Medication Old Medication Diference btw treatments
F0-F3 35.025.033 € 23.468.912 € 11.556.121 €
Cirrhosis (F4) 34.487.034 € 20.030.256 € 14.456.779 €
Hepatic Decompensation 122.268.038 € 70.669.019 € 51.599.019 €
HCC 37.147.936 € 21.516.032 € 15.631.903 €
Liver Transplant 178.898.901 € 102.749.915 € 76.148.986 €
Total 407.826.941 € 238.434.133 € 169.392.808 €
Total per Patient 40.109 € 23.449 € 16.659 €
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20.000€ per treatment, is the more realistic according to the press and results in a total cost of 
therapy of 203.362.366€, which allows the government to save 45.853.172€ in costs between 
treatments and 4.510€ per patient. Lastly, a more unrealistic scenario of 15.000€ per treatment 
would prevent the government from spending more 96.693.172€ fighting the disease, saving 
9.510€ per patient. 
As it is possible to observe, since costs with non-SVR patients in old medication are way 
higher than with new medication, in all scenarios a higher cost per treatment with the new 
therapy is not enough for the government to lose money in the long-run, resulting in a great 
amount of savings. (Table 13). 
 
Table 13- Sensitivity analysis for different costs of the new therapy (designed from data) 
4.6 QALYs and ICER 
The new medication will increase the number of Quality-Adjusted Life-Years in a sixty 
years period to 89.161, when comparing with the 56.592 QALYs obtained with the old therapy. 
The difference between treatments is therefore 32.568, being QALYs discounted at a 5% rate, 
increasing average life expectancy of HCV infected patients in 3.2 years. Expected costs with 
the new medication are lower, a result of a higher SVR rate with the new treatment.  
For the three scenarios (Table 14), different Incremental Cost-Effectiveness Ratios were 
calculated, being -159€/QALY in the first one, -1.408€/QALY in the second one and -2.969€ 
in the last hypothesis. If respecting NICE rules of a maximum threshold of £30.000/QALY, the 
three scenarios would fit the regulations, being the new treatment considered as cost-effective.  
Plus, given the great amount of benefits brought by the new medication in terms of 
occurrences avoided, reduction in public expenditure or even non-responding patients to the 
old treatment that become cured, the recommendation is very positive. 
SOF / LDV = 24.000€ New Medication Old Medication Diference
Cost of therapy 244.034.336 € 79.822.699 € 164.211.636 €
Costs of non-responding patients 22.602.091 € 191.994.899 € -169.392.808 €
Total 266.636.426 € 271.817.598 € -5.181.172 €
Total Cost per patient 26.223 € 26.733 € -510 €
SOF / LDV = 20.000€ New Medication Old Medication Diference
Cost of therapy 203.362.336 € 79.822.699 € 123.539.636 €
Costs of non-responding patients 22.602.091 € 191.994.899 € -169.392.808 €
Total 225.964.426 € 271.817.598 € -45.853.172 €
Total Cost per patient 22.223 € 26.733 € -4.510 €
SOF / LDV = 15.000€ New Medication Old Medication Diference
Cost of therapy 152.522.336 € 79.822.699 € 72.699.636 €
Costs of non-responding patients 22.602.091 € 191.994.899 € -169.392.808 €
Total 175.124.426 € 271.817.598 € -96.693.172 €
Total Cost per patient 17.223 € 26.733 € -9.510 €
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Table 14 - Expected QALYs and ICER for the two treatments given the three different cost levels (designed 
from data) 
 
4.7 Sensitivity Analysis for different discount rates 
Taking into consideration Infarmed regulations for economic healthcare analysis, two 
different Sensitive Analysis were performed for 0% and 3% discount rates. 
4.7.1 Sensitivity Analysis for a 0% discount rate 
With a 0% discount rate, costs for non-responding patients will be significantly higher than 
for 5%, increasing the reduction in public expenditure when comparing to the former discount 
rate (Table 15). Considering the three different new therapy cost levels, when the price of 
medication is 24.000€, the total savings between therapies amount 146.141.357€, or 14.373€ 
per patient, while when cost is 20.000€, the government can save 186.813.357€, 18.373€ per 
patient. Lastly, when Sofosbuvir / Ledipasvir costs 15.000€ per treatment, the government 
saves 237.653.357€, meaning 23.373€ per patient.  
 
Table 15 - Sensitivity analysis for different costs of the new therapy using a 0% discount rate (designed from 
data) 
SOF / LDV = 24.000€ New Medication Old Medication Diference btw treatments
Expected Cost 266.636.426 € 271.817.598 € -5.181.172 €
Expected QALYs 89.161 56.592 32.568
ICER (€ per QALY) -159 €
QALY per patient 8,77 5,57 3,20
SOF / LDV = 20.000€ New Medication Old Medication Diference btw treatments
Expected Cost 225.964.426 € 271.817.598 € -45.853.172 €
Expected QALYs 89.161 56.592 32.568
ICER (€ per QALY) -1.408 €
QALY per patient 8,77 5,57 3,20
SOF / LDV = 15.000€ New Medication Old Medication Diference btw treatments
Expected Cost 175.124.426 € 271.817.598 € -96.693.172 €
Expected QALYs 89.161 56.592 32.568
ICER (€ per QALY) -2.969 €
QALY per patient 8,77 5,57 3,20
SOF / LDV = 24.000€  (DR=0%) New Medication Old Medication Diference
Cost of therapy 244.034.336 € 65.670.332 € 178.364.003 €
Costs of non-responding patients 40.845.321 € 365.350.681 € -324.505.360 €
Total 284.879.656 € 431.021.013 € -146.141.357 €
Total Cost per patient 28.017 € 42.390 € -14.373 €
SOF / LDV = 20.000€ (DR=0%) New Medication Old Medication Diference
Cost of therapy 203.362.336 € 65.670.332 € 137.692.003 €
Costs of non-responding patients 40.845.321 € 365.350.681 € -324.505.360 €
Total 244.207.656 € 431.021.013 € -186.813.357 €
Total Cost per patient 24.017 € 42.390 € -18.373 €
SOF / LDV = 15.000€ (DR=0%) New Medication Old Medication Diference
Cost of therapy 152.522.336 € 65.670.332 € 86.852.003 €
Costs of non-responding patients 40.845.321 € 365.350.681 € -324.505.360 €
Total 193.367.656 € 431.021.013 € -237.653.357 €
Total Cost per patient 19.017 € 42.390 € -23.373 €
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Discounted QALYs will suffer a reduction, influenced by the drop of the discount rate, 
amounting 155.688 in the new therapy and 99.171 in the old therapy. The difference between 
treatments will therefore increase to 56.517 rising the life expectancy for Hepatitis C infected 
patients to 5,56 years. 
The Incremental Cost-Effectiveness Ratio will also be influenced by the increase in total 
costs and decrease substantially to -2.586€ per QALY in the first scenario, -3.305€ per QALY 
in the second and -4.205€ per QALY in the third situation (Table 16). However, the outcome 
is still negative, meaning that the change in therapies is still cost effective.  
 
Table 16 - Expected QALYs and ICER for the two treatments given the three different cost levels (0% 
Discount Rate) (designed from data) 
Total lifetime savings will also increase to 324.505.360€, a result of the significant drops in 
costs sixty years from now. With this discount rate, the difference in savings per patient when 
using the new therapy will be 31.914€ (Table 17). 
 
Table 17 - Lifetime Savings given a 0% Discount Rate (designed from data) 
 
4.7.2 Sensitivity Analysis for a 3% discount rate 
On the other side, when using a 3% discount rate the results are between the ones calculated 
for the 0% and 5% discount rates. In the first scenario, a 24.000€ cost level returns a total 
difference in savings between therapies of 43.228.776€ and savings of 4.251€ per patient, while 
the second scenario of 20.000€ in costs allows the government to save 83.900.776€, 8.251€ per 
patient in the end of the 60 years. The last scenario, 15.000€ per therapy, returns a profit of 
134.740.776€, 13.251€ per patient (Table 18). 
SOF / LDV = 24.000€ (DR=0%) New Medication Old Medication Diference btw treatments
Expected Cost 284.879.656 € 431.021.013 € -146.141.357 €
Expected QALYs 155.688 99.171 56.517
ICER (€ per QALY) -2.586 €
QALY per patient 15,31 9,75 5,56
SOF / LDV = 20.000€ (DR=0%) New Medication Old Medication Diference btw treatments
Expected Cost 244.207.656 € 431.021.013 € -186.813.357 €
Expected QALYs 155.688 99.171 56.517
ICER (€ per QALY) -3.305 €
QALY per patient 15,31 9,75 5,56
SOF / LDV = 15.000€ (DR=0%) New Medication Old Medication Diference btw treatments
Expected Cost 193.367.656 € 431.021.013 € -237.653.357 €
Expected QALYs 155.688 99.171 56.517
ICER (€ per QALY) -4.205 €
QALY per patient 15,31 9,75 5,56
Lifetime Savings (DR=0%) New Medication Old Medication Diference in treatments
Total 800.909.609 € 476.404.249 € 324.505.360 €
Total per Patient 78.768 € 46.853 € 31.914 €
35 
 
 
Table 18 - Sensitivity analysis for different costs of the new therapy using a 3% discount rate (designed from 
data) 
QALYs will also rise when compared to the previous analysis (0% discount rate), a result 
of the increase in the discount rate. New Medication will return QALYs of 108.465 and Old 
Medication of 68.932. The difference in QALYs gained between treatments is lower when 
compared to the 0% discount rate, 39.534, which will extend life expectancy in 3,89 years 
(Table 19). 
The ICER increases when facing a 3% discount rate, and is -1.093€/QALY in the first 
scenario, -2.122€/QALY in the second scenario and -3.408€/QALY in the third scenario. The 
three ICER results calculated for the different therapy cost levels are still negative, meaning 
that the treatment is still cost-effective. 
 
Table 19- Expected QALYs and ICER for the two treatments given the three different cost levels (3% 
Discount Rate) (designed from data) 
 
SOF / LDV = 24.000€  (DR=3%) New Medication Old Medication Diference
Cost of therapy 244.034.336 € 73.912.537 € 170.121.798 €
Costs of non-responding patients 27.870.065 € 241.220.639 € -213.350.574 €
Total 271.904.400 € 315.133.176 € -43.228.776 €
Total Cost per patient 26.741 € 30.993 € -4.251 €
SOF / LDV = 20.000€  (DR=3%) New Medication Old Medication Diference
Cost of therapy 203.362.336 € 73.912.537 € 129.449.798 €
Costs of non-responding patients 27.870.065 € 241.220.639 € -213.350.574 €
Total 231.232.400 € 315.133.176 € -83.900.776 €
Total Cost per patient 22.741 € 30.993 € -8.251 €
SOF / LDV = 15.000€  (DR=3%) New Medication Old Medication Diference
Cost of therapy 152.522.336 € 73.912.537 € 78.609.798 €
Costs of non-responding patients 27.870.065 € 241.220.639 € -213.350.574 €
Total 180.392.400 € 315.133.176 € -134.740.776 €
Total Cost per patient 17.741 € 30.993 € -13.251 €
SOF / LDV = 24.000€ (DR=3%) New Medication Old Medication Diference btw treatments
Expected Cost 271.904.400 € 315.133.176 € -43.228.776 €
Expected QALYs 108.465 68.932 39.534
ICER (€ per QALY) -1.093 €
QALY per patient 10,67 6,78 3,89
SOF / LDV = 20.000€ (DR=3%) New Medication Old Medication Diference btw treatments
Expected Cost 231.232.400 € 315.133.176 € -83.900.776 €
Expected QALYs 108.465 68.932 39.534
ICER (€ per QALY) -2.122 €
QALY per patient 10,67 6,78 3,89
SOF / LDV = 15.000€ (DR=3%) New Medication Old Medication Diference btw treatments
Expected Cost 180.392.400 € 315.133.176 € -134.740.776 €
Expected QALYs 108.465 68.932 39.534
ICER (€ per QALY) -3.408 €
QALY per patient 10,67 6,78 3,89
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Lifetime savings are now 518.439.502€ with New Medication and 305.088.939€ with the 
Old Medication, meaning that the difference between treatments is 213.350.563€. The 
difference in savings by treating patients with the new therapy decreases to 20.983€ when 
compared to a 0% discount rate (Table 20).  
 
Table 20 - Lifetime Savings given a 3% Discount Rate (designed from data) 
 
4.8 Decision to change therapies 
Summing up, as it is possible to understand from the table below (Table 21), differences 
between therapies’ total costs decrease as the discount rate increases. The same phenomenon is 
possible to detect when the cost of the new therapy decreases. As a result, the total difference 
in costs between therapies and therefore the difference per patient is negative, meaning that the 
government will always save money with the new medication. 
 
Table 21- Differences in costs for different discount rates and different cost levels (designed from data) 
 
Lifetime Savings from responding patients become higher as the discount rate decrease. 
Difference between treatments is 16.659€ per patient in the worst case scenario, a positive 
indicator. Plus, costs are always higher with the new medication rather than with the old one, 
meaning that there will be always a surplus to the government.   
 
Table 22 - Differences in Lifetime Savings for different discount rates (designed from data) 
 
Lifetime Savings (DR=3%) New Medication Old Medication Diference in treatments
Total 518.439.502 € 305.088.939 € 213.350.563 €
Total per Patient 50.987 € 30.005 € 20.983 €
NM OM Difference Difference / Patient
DR = 0% 193.367.656 € 431.021.013 € -237.653.357 € -23.373 €
DR = 3% 180.392.400 € 315.133.176 € -134.740.776 € -13.251 €
DR = 5% 175.124.426 € 271.817.598 € -96.693.172 € -9.510 €
DR = 0% 244.207.656 € 431.021.013 € -186.813.357 € -18.373 €
DR = 3% 231.232.400 € 315.133.176 € -83.900.776 € -8.251 €
DR = 5% 225.964.426 € 271.817.598 € -45.853.172 € -4.510 €
DR = 0% 284.879.656 € 431.021.013 € -146.141.357 € -14.373 €
DR = 3% 271.904.400 € 315.133.176 € -43.228.776 € -4.251 €
DR = 5% 266.636.426 € 271.817.598 € -5.181.172 € -510 €
Total Costs
24.000 €
20.000 €
15.000 €
New Medication Old Medication Diference btw treatments
Total 800.909.609 € 476.404.249 € 324.505.360 €
Total per Patient 78.768 € 46.853 € 31.914 €
Total 518.439.502 € 305.088.939 € 213.350.563 €
Total per Patient 50.987 € 30.005 € 20.983 €
Total 407.826.941 € 238.434.133 € 169.392.808 €
Total per Patient 40.109 € 23.449 € 16.659 €
DR = 0%
Lifetime Savings
DR = 3%
DR = 5%
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The difference between expected QALYs decreases with the growth of the discount rate, 
being the maximum difference in QALYs achieved of 56.517. QALYs per patient vary between 
5,56 and 3,20. The Incremental Cost-Effectiveness Ratio is always negative for the different 
cost levels and discount rates, meaning that investing in the new therapy (Sovaldi® and 
Harvoni®) is always cost-effective (Table 23). ICER is the lowest for a 24.000€ cost level and 
a 5% discount rate, and the highest for a 15.000€ cost level and 0% discount rate. 
 
Table 23- Differences in QALYs and ICER for different discount rates and cost levels (designed from data) 
 
In the end, regardless of the discount rate or the new therapy cost per patient, it will always 
be worth to the government to grant universal access to Sofosbuvir and Sofosbuvir + 
Ledipasvir. The average life expectancy of Hepatitis C infected patients will increase and the 
new therapy will always be cost effective, meaning that, 60 years from now, the government 
will have saved more lives with less money. 
 
0% 3% 5%
Total 56.517 39.534 32.568
Per Patient 5,56 3,89 3,20
15.000 € -4.205 € -3.408 € -2.969 €
20.000 € -3.305 € -2.122 € -1.408 €
24.000 € -2.586 € -1.093 € -159 €
ICER
Differences in QALYs and ICER (NM vs OM)
QALY
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5. Conclusions, Limitations and Future Research 
5.1 Conclusions 
The old medication for the treatment of Hepatitis C, Pegylated Interferon + Ribavirin, was 
in the past a great improvement in the eradication of the virus allowing HCV infected patients 
to become cured. However, this treatment has only a modest efficacy for most patients and 
important side effects, preventing many people to be cured. 
After a failed experience with two new drugs, Boceprevir and Telaprevir, mainly due to its 
serious side effects, Gilead developed Sofosbuvir (Sovaldi®) and Sofosbuvir + Ledipasvir 
(Harvoni®), promising SVR rates around 95%. These new medications gave a new hope for 
many patients unable to become cured from the infection and motivated several public 
demonstrations while the government and the pharmaceutical company were agreeing on 
prices. 
After some months of expectation, the Portuguese Health Minister informed the Portuguese 
citizens that the agreement with Gilead was signed, being the best in Europe until that moment. 
The government would only pay for the treated patients and the same per patient regardless of 
the duration of the treatment. The cost of the therapy was not disclosed although press rumors 
pointed to 20.000€-24.000€. Therefore, in order to do a complete economic evaluation of this 
political action, a sensitivity analysis for the three different levels of price had to be performed. 
Since Hepatitis C is a disease with multiple stages, in order to calculate the costs and the 
savings of the new therapy when compared to the old one, a Markov model had to be computed. 
Annual transition probabilities between states were attributed to the model, as well as Quality 
of Life Utilities. This way, it was possible to calculate the results for a 60 years period, the time 
all the patients in the model needed to transit to the death stage. In the end, by attributing cost 
values to all the states, obtained in literature, and discounting to the present value both the costs 
and the QALYs it was possible to obtain the outcomes of the model. 
When performing this economic analysis, it was interesting to analyze whether the fact that 
being the new therapy cost per patient significantly higher than the old one, could be enough to 
overcome the potential difference gained in lifetime savings in patients between the two 
therapies, therefore not being cost-effective. Results however completely dismissed this 
questions as they showed that the therapy is cost-effective for all discount rates applied to the 
model, since the more effective SVR rate influences costs of non-treated patients with the new 
medication to decrease substantially when compared to the former medication. 
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What is more, this new therapy will provide savings in occurrences of 169.392.808 €, 16.659 
€ per patient when compared with the old therapy. Even when computing a sensitivity analysis 
for the three different new therapy cost levels chosen for comparison, 15.000€, 20.000€ and 
24.000€, costs were always inferior to the previous medicine, still a consequence of the 
difference in the non-treated patients. Treating patients with this new therapy will allow the 
government to save 510€ per patient for the highest old therapy cost level, the worst case 
scenario. Nevertheless, the more realistic cost levels will allow savings in the order of 4.510€ 
per patient and 9.510€ per patient, respectively.  
As it is clear to understand, this new medicine is extremely cost effective for the 
government, as not only it is able to reduce costs when compared to the old therapy, as it will 
provide several benefits by allowing the National Healthcare System to save a great amount of 
money. Nevertheless, one should not forget that when taking healthcare political decisions, 
most of the times the economical factor is not the most important to take into consideration. 
This new therapy will be able to reduce the number of occurrences, especially in the most 
advanced stages of the disease, avoiding up to 1083 Hepatocellular Carcinomas, 286 Liver 
Transplants and 3737 premature HCV-related deaths. Sovaldi® and Harvoni® will also 
contribute for an increase in the life expectancy of HCV infected patients of 3,2 years. Plus, 
several patients that did not cured the infection when using the old treatment have now a second 
chance of becoming cured.  
In conclusion, it is worth for the government to invest in this new therapy. Initial costs will 
be higher, a consequence of treating all patients not only those on the more advanced stages 
and of a higher cost per treatment. Nevertheless, the difference in the costs of non-responding 
patients in the long term completely justifies this measure, allowing savings in the long run. 
This measure will also definitely reshape the way businesses between the Health Ministry 
and pharmaceutical companies are conducted. By paying exclusively the amount per treated 
patient, the government can use this deal as a role model for future drugs negotiations. Also, 
the government learned that by negotiating in a mass scale, curing all patients infected with the 
disease instead of those in the most advanced stages, benefits can be very significant in the long 
term. 
5.2 Limitations and Future Research 
Throughout this dissertation, some limitations affected the way the study was conducted, 
preventing a deeper analysis.  
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The first one was the reluctance of the Infarmed on providing the data contained in its portal 
what would allow a better characterization of the patients and the response to treatment.  
Some simplifications regarding the Markov model were conducted, so that the numeric 
analysis become easier. Concerning the cirrhotic patients with SVR, for instance, the reduced 
risk for progression to HCC was not considered. The transition probability after Liver 
Transplantation to the death stage was related only to the first year, despite being the year more 
people died as consequence of it.  
In the future, a more detailed analysis of the patients could be helpful. By getting the HCV 
portal data, researchers can easily estimate SVR rates for different age groups and gender. This 
is essential to observe and analyze the impact of medications over a time period. Also, by 
increasing more and more the complexity of the Markov model, it is possible to obtain even 
more accurate results, closer to the reality.  
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6. Appendixes 
6.1 Appendix 1 – QALYs 
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6.2 Appendix 2 - Example of a EQ-5D Questionnaire 
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6.3 Appendix 3 - ICER 
 
 
Source: Hepatitis C Online – University of Washington 
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6.4 Appendix 4 – Markov Model 
 
 
Source: Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's disease 
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